Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/22146
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorDARTORA, Daniela Ravizzoni-
dc.contributor.authorIRIGOYEN, Maria-Claudia-
dc.contributor.authorCASALI, Karina Rabello-
dc.contributor.authorMORAES-SILVA, Ivana C.-
dc.contributor.authorBERTAGNOLLI, Mariane-
dc.contributor.authorBADER, Michael-
dc.contributor.authorSANTOS, Robson A. S.-
dc.date.accessioned2017-10-24T13:23:46Z-
dc.date.available2017-10-24T13:23:46Z-
dc.date.issued2017-
dc.identifier.citationCANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, v.95, n.9, p.993-998, 2017-
dc.identifier.issn0008-4212-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/22146-
dc.description.abstractAngiotensin-(1-7) counterbalances angiotensin II cardiovascular effects. However, it has yet to be determined how cardiovascular autonomic modulation may be affected by chronic and acute elevation of Ang-(1-7). Hemodynamics and cardiovascular autonomic profile were evaluated in male Sprague-Dawley (SD) rats and transgenic rats (TGR) overexpressing Ang-(1-7) [TGR(A1-7) 3292]. Blood pressure (BP) was directly measured while cardiovascular autonomic modulation was evaluated by spectral analysis. TGR received A-779 or vehicle and SD rats received Ang-(1-7) or vehicle and were monitored for 5 h after i.v. administration. In another set of experiments with TGR, A-779 was infused for 7 days using osmotic mini pumps. Although at baseline no differences were observed, acute administration of A-779 in TGR produced a marked long-lasting increase in BP accompanied by increased BP variability (BPV) and sympathetic modulation to the vessels. Likewise, chronic administration of A-779 with osmotic mini pumps in TGR increased heart rate, sympathovagal balance, BPV, and sympathetic modulation to the vessels. Administration of Ang-(1-7) to SD rats increased heart rate variability values in 88% accompanied by 8% of vagal modulation increase and 18% of mean BP reduction. These results show that both acute and chronic alteration in the Ang-(1-7)-Mas receptor axis may lead to important changes in the autonomic control of circulation, impacting either sympathetic and (or) parasympathetic systems.-
dc.description.sponsorshipCAPES-
dc.description.sponsorshipFAPEMIG-
dc.description.sponsorshipCNPQ-
dc.description.sponsorshipFAPERGS-
dc.language.isoeng-
dc.publisherCANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS-
dc.relation.ispartofCanadian Journal of Physiology and Pharmacology-
dc.rightsrestrictedAccess-
dc.subjectrenin-angiotensin system-
dc.subjectangiotensin-(1-7)-
dc.subjectA-779-
dc.subjectblood pressure-
dc.subjectautonomic nervous system-
dc.subjectheart rate variability-
dc.subjectspectral analysis-
dc.subject.otherrenin-angiotensin system-
dc.subject.otherbaroreceptor reflex modulation-
dc.subject.otherheart-rate-variability-
dc.subject.otherhypertensive-rats-
dc.subject.otherblood-pressure-
dc.subject.othercirculating angiotensin-(1-7)-
dc.subject.otherbaroreflex modulation-
dc.subject.otherinfusion-
dc.subject.otherstress-
dc.subject.othermice-
dc.titleImproved cardiovascular autonomic modulation in transgenic rats expressing an Ang-(1-7)-producing fusion protein-
dc.typearticle-
dc.rights.holderCopyright CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS-
dc.identifier.doi10.1139/cjpp-2016-0557-
dc.identifier.pmid28459154-
dc.subject.wosPharmacology & Pharmacy-
dc.subject.wosPhysiology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalDARTORA, Daniela Ravizzoni:Univ Fdn Cardiol, Cardiol Inst Rio Grande Sul, Porto Alegre, RS, Brazil-
hcfmusp.author.externalCASALI, Karina Rabello:Univ Fdn Cardiol, Cardiol Inst Rio Grande Sul, Porto Alegre, RS, Brazil; Fed Univ Sao Paulo UNIFESP, Sci & Technol Inst ICT, Sao Paulo, Brazil-
hcfmusp.author.externalBERTAGNOLLI, Mariane:CHU St Justine Res Ctr, Montreal, PQ, Canada-
hcfmusp.author.externalBADER, Michael:Max Delbruck Ctr Mol Med MDC, Berlin, Germany-
hcfmusp.author.externalSANTOS, Robson A. S.:Univ Fdn Cardiol, Cardiol Inst Rio Grande Sul, Porto Alegre, RS, Brazil; Univ Fed Minas Gerais, Natl Inst Sci & Technol Nanobiopharm, Inst Biol Sci, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil-
hcfmusp.description.beginpage993-
hcfmusp.description.endpage998-
hcfmusp.description.issue9-
hcfmusp.description.volume95-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000408322600002-
hcfmusp.origem.id2-s2.0-85019708744-
hcfmusp.publisher.cityOTTAWA-
hcfmusp.publisher.countryCANADA-
hcfmusp.relation.referenceAlzamora AC, 2006, AM J PHYSIOL-REG I, V290, pR1027, DOI 10.1152/ajpregu.00852.2004-
hcfmusp.relation.referenceBaltatu OC, 2011, PEPTIDES, V32, P1083, DOI 10.1016/j.peptides.2011.02.008-
hcfmusp.relation.referenceBertagnolli M, 2014, PEPTIDES, V51, P65, DOI 10.1016/j.peptides.2013.11.006-
hcfmusp.relation.referenceBotelho-Santos GA, 2007, AM J PHYSIOL-HEART C, V292, pH2485, DOI 10.1152/ajpheart.01245.2006-
hcfmusp.relation.referenceBraga ANG, 2002, AM J PHYSIOL-REG I, V282, pR1663, DOI 10.1152/ajpregu.00583.2001-
hcfmusp.relation.referenceBritto RR, 1997, HYPERTENSION, V30, P549-
hcfmusp.relation.referenceCAMPAGNOLESANTOS MJ, 1992, AM J PHYSIOL, V263, pR89-
hcfmusp.relation.referenceCAMPAGNOLESANTOS MJ, 1988, HYPERTENSION, V11, P167-
hcfmusp.relation.referenceFazan R, 2005, AM J PHYSIOL-HEART C, V289, pH1968, DOI 10.1152/ajpheart.01224.2004-
hcfmusp.relation.referenceFeng YM, 2010, CIRC RES, V106, P373, DOI 10.1161/CIRCRESAHA.109.208645-
hcfmusp.relation.referenceFerrario CM, 2011, CURR OPIN NEPHROL HY, V20, P1, DOI 10.1097/MNH.0b013e3283406f57-
hcfmusp.relation.referenceFerreira AJ, 2011, J HISTOCHEM CYTOCHEM, V59, P761, DOI 10.1369/0022155411411712-
hcfmusp.relation.referenceFraga-Silva RA, 2008, MOL MED, V14, P28, DOI 10.2119/2007-00073.Fraga-Silva0-
hcfmusp.relation.referenceFreeman EJ, 1996, HYPERTENSION, V28, P104-
hcfmusp.relation.referenceGuimaraes GG, 2012, PEPTIDES, V38, P54, DOI 10.1016/j.peptides.2012.05.024-
hcfmusp.relation.referenceHerath CB, 2013, AM J PHYSIOL-GASTR L, V304, pG99, DOI 10.1152/ajpgi.00163.2012-
hcfmusp.relation.referenceKlein N, 2013, CRIT CARE MED, V41, pE334, DOI 10.1097/CCM.0b013e31828a6688-
hcfmusp.relation.referenceKluskens LD, 2009, J PHARMACOL EXP THER, V328, P849, DOI 10.1124/jpet.108.146431-
hcfmusp.relation.referenceLautner RQ, 2013, CIRC RES, V112, P1104, DOI 10.1161/CIRCRESAHA.113.301077-
hcfmusp.relation.referenceMALLIANI A, 1991, CIRCULATION, V84, P482-
hcfmusp.relation.referenceXavier C. H., 2013, AM J PHYSIOL-HEART C, V305, pH1057, DOI [10.1152/ajpheart.00433.2013, DOI 10.1152/AJPHEART.00433.2013]-
hcfmusp.relation.referenceMcKinley MJ, 2003, INT J BIOCHEM CELL B, V35, P901, DOI 10.1016/S1357-2725(02)00306-0-
hcfmusp.relation.referenceMoraes-Silva IC, 2010, CLIN EXP PHARMACOL P, V37, pe114, DOI 10.1111/j.1440-1681.2009.05333.x-
hcfmusp.relation.referenceMoreira ED, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.45-
hcfmusp.relation.referenceNational Research Council, 2011, GUIDE CARE USE LAB A, DOI [10.17226/12910, DOI 10.17226/12910]-
hcfmusp.relation.referenceOliveira DR, 1996, HYPERTENSION, V27, P1284-
hcfmusp.relation.referenceOscar CG, 2015, BRAIN RES, V1594, P183, DOI 10.1016/j.brainres.2014.11.006-
hcfmusp.relation.referenceOudit GY, 2003, TRENDS CARDIOVAS MED, V13, P93, DOI 10.1016/S1050-1738(02)00233-5-
hcfmusp.relation.referencePagani M, 1997, CIRCULATION, V95, P1441-
hcfmusp.relation.referencePARATI G, 1995, HYPERTENSION, V25, P1276-
hcfmusp.relation.referenceReudelhuber TL, 2011, HYPERTENSION, V57, P532, DOI 10.1161/HYPERTENSIONAHA.110.167114-
hcfmusp.relation.referenceSampaio WO, 2003, AM J PHYSIOL-HEART C, V284, pH1985, DOI 10.1152/ajpheart.01145.2002-
hcfmusp.relation.referenceSantiago NM, 2010, HYPERTENSION, V55, P889, DOI 10.1161/HYPERTENSIONAHA.110.149815-
hcfmusp.relation.referenceSantos RAS, 2004, PHYSIOL GENOMICS, V17, P292, DOI 10.1152/physiolgenomics.00227.2003-
hcfmusp.relation.referenceSantos RAS, 2008, EXP PHYSIOL, V93, P519, DOI 10.1113/expphysiol.2008.042002-
hcfmusp.relation.referenceSantos RA, 2014, HYPERTENSION, V63, P1138, DOI 10.1161/HYPERTENSIONAHA.113.01274-
hcfmusp.relation.referenceSantos SHS, 2010, ARTERIOSCL THROM VAS, V30, P953, DOI 10.1161/ATVBAHA.109.200493-
hcfmusp.relation.referenceSilva DMR, 2007, PEPTIDES, V28, P702, DOI 10.1016/j.peptides.2006.10.007-
hcfmusp.relation.referenceSimoes ES, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/BPH.12159-
hcfmusp.relation.referenceSantos SHS, 2014, PEPTIDES, V59, P34, DOI 10.1016/j.peptides.2014.07.002-
hcfmusp.relation.referenceZimmerman MC, 2004, CIRC RES, V95, P210, DOI 10.1161/01.RES.0000135483.12297.e4-
dc.description.indexMEDLINE-
dc.identifier.eissn1205-7541-
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2024-03-08-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/59
LIM/59 - Laboratório de Biologia Celular


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.